Back to search
FDAFDA · Food and drugs·Recall number D-0888-2022

Zonisamide Capsules USP, 100 mg, 90-count bottle, Rx Only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 61919-775-90

Published June 1, 2022 · Recall initiated: May 13, 2022

Summary

FDA records drug Class II recall D-0888-2022, published June 1, 2022 and initiated May 13, 2022. Recalling firm: Direct Rx; Status: Terminated; Reported quantity: 16 bottles; Lot: Lot: 23JY2124 Exp. 6/30/23. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
Nationwide to the U.S. market
Lot
Lot: 23JY2124 Exp. 6/30/23
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Zonisamide Capsules USP, 100 mg, 90-count bottle, Rx Only, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 61919-775-90 recalled?

Yes. FDA published recall D-0888-2022 on June 1, 2022. Reported hazard: CGMP Deviations: Gaps in the quality system in the Quality Control microbiology laboratory.

What should I do if I have this product?

Voluntary: Firm initiated · Letter